161777-86-2

Upstream product

• 98-60-2 4-chlorobenzenesulfonyl chloride 
• 161778-38-7 3-[3-(2-Carbamoyl-ethyl)-5-(4-fluoro-benzoyl)-phenyl]-propionic acid ethyl ester 
• 459-57-4 4-fluorobenzaldehyde 
• 161777-98-6 3,5-dibromo-α-(4-fluorophenyl)benzenemethanol 
• 161778-27-4 diethyl 5-[(4-fluorophenyl)hydroxymethyl]-1,3-benzenedipropanoate 
• 161778-29-6 diethyl 5-(4-fluorobenzoyl)-1,3-benzenedipropanoate 
• 214406-52-7 (E)-3-{3-((E)-2-Ethoxycarbonyl-vinyl)-5-[(4-fluoro-phenyl)-hydroxy-methyl]-phenyl}-acrylic acid ethyl ester 
• 161778-33-2 3-[3-(2-Ethoxycarbonyl-ethyl)-5-(4-fluoro-benzoyl)-phenyl]-propionic acid 
• 626-39-1 1,3,5-trisbromobenzene 

Downstream Products

• 161777-88-4 3-[2-[(4-chlorophenyl)sulphonylamino]ethyl]-5-(4-methoxybenzoyl)benzenepropanoic acid 
• 161777-89-5 3-[2-[(4-Chlorophenyl)sulphonylamino]ethyl]-5-(4-methylsulphonylbenzoyl)benzenepropanoic acid 

Relevant academic research and scientific papers

Thromboxane modulating agents. 4. Design and synthesis of 3-(2-[{(4- chlorophenyl)sulfonyl}-amino]ethyl)benzenepropanoic acid derivatives as potent thromboxane receptor antagonists

The design of a series of thromboxane receptor antagonists based on 3- (2-[{(4-chlorophenyl)sulfonyl}amino]ethyl)benzenepropanoic acid (1) is described. Addition of an arylmethyl group at the 5-position of 1 gave exceptionally potent agents in vitro and in vivo, with 13a (UK-147,535) giving complete blockade of the TxA2 receptor for greater than 12 hours in dogs, following an oral dose of 0.1 mg/kg.